Nasdaq

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the world.
Morningstar

Sapphiros announces a strategic agreement with Roche, providing Roche access to 1 billion lateral flow tests and access to future molecular point-of-care tests

Agreement secures rapid, global access to tests for future pandemics and health emergencies Under the agreement, Roche gains access to at least 1 billion tests annually from Sapphiros' 5 billion unit ...
Morningstar

Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin's Lymphoma

BOULDER, Colo., Aug. 29, 2025 /PRNewswire/ -- Foresight Diagnostics ("Foresight") today announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche ...
Nasdaq

Roche receives CE Mark for new, updated molecular cobs 6800/8800 systems

Roche (RHHBY) announced the CE certification of the new cobas 6800/8800 systems 2.0. The update significantly enhances the efficiency of laboratories by optimizing resources, reducing downtime, ...
Fierce Biotech

Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales

Full-year sales for Roche’s diagnostics division were up by just 2% as the Big Pharma deals with ongoing challenges in China.  | Full-year sales for Roche’s diagnostics division were up by just 2% as ...